Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future?

Trends Pharmacol Sci. 1997 May;18(5):164-71. doi: 10.1016/s0165-6147(97)01049-3.

Abstract

Phosphodiesterase type 4 (PDE4) plays a major role in modulating the activity of virtually all cells involved in the inflammatory process. Inhibitors of this enzyme family display impressive anti-inflammatory and disease-modifying effects in a variety of experimental models. In this review, Mauro Teixeira, Robert Gristwood, Nicola Cooper and Paul Hellewell examine the capacity of PDE4 inhibitors to exert anti-inflammatory actions in vivo and discuss the potential of this class of drugs to take their place as novel therapeutic agents for a variety of inflammatory diseases.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • 3',5'-Cyclic-AMP Phosphodiesterases*
  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal / pharmacology*
  • Cyclic Nucleotide Phosphodiesterases, Type 4
  • Humans
  • Isoenzymes / antagonists & inhibitors*
  • Phosphodiesterase Inhibitors / pharmacology*
  • Phosphoric Diester Hydrolases / metabolism*

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Isoenzymes
  • Phosphodiesterase Inhibitors
  • Phosphoric Diester Hydrolases
  • 3',5'-Cyclic-AMP Phosphodiesterases
  • Cyclic Nucleotide Phosphodiesterases, Type 4